文献速递肿瘤 PET/CT放射性药物与辐射防护

结核病的分子影像

Molecular Imaging of Tuberculosis.
PubMed 文献 · Semin Nucl Med · 2022-07-23

本文综述结核病分子影像的进展。氟-18氟代脱氧葡萄糖(FDG)正电子发射断层与计算机断层显像(PET/CT)在预测治疗结局方面优于痰菌转阴,并能在治疗结束时识别按现行标准判定治愈但仍携带活菌、停药后可能复发的一部分患者。FDG为非特异性探针,目前正在评估针对结核肉芽肿缺氧、新生血管和纤维化的新型探针,以及放射性标记抗结核药物用于药物动力学研究。

要点

  • FDG PET/CT预测结核治疗结局优于痰菌转阴。
  • 治疗结束时FDG PET/CT可识别按现行标准判定治愈但仍带活菌、停药后可能复发的一部分患者。
  • 正在评估靶向结核肉芽肿缺氧、新生血管和纤维化的新型探针。

核心结论

  • FDG PET/CT在预测结核治疗结局方面优于痰菌转阴,并能在治疗结束时识别按现行标准判定治愈但仍携带活菌、停药后可能复发的一部分患者。
  • FDG靶向宿主对结核分枝杆菌的炎症反应,在结核与其他感染性疾病之间不具有特异性。
  • 目前正在评估靶向结核肉芽肿缺氧、新生血管和纤维化的新型探针在结核管理中的效用。
  • 放射性标记抗结核药物用于研究药物动力学,是较有前景的非FDG PET探针类别。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 全球约四分之一人口携带结核分枝杆菌。
  • FDG PET/CT预测结核治疗结局优于痰菌转阴。
  • 治疗结束时FDG PET/CT可识别按现行标准判定治愈但仍携带活菌、停药后可能复发的一部分患者。
  • 放射性标记抗结核药物可无创地同时研究不同身体隔室的药物动力学,反映不同结核病灶药物暴露的空间异质性。
  • 重复分子影像可研究治疗期间不同病灶内药物动力学的时间变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the introduction of many novel diagnostic techniques and newer treatment agents, tuberculosis (TB) remains a major cause of death from an infectious disease worldwide. With about a quarter of humanity harboring Mycobacterium tuberculosis, the causative agent of TB, the current efforts geared towards reducing the scourge due to TB must be sustained. At the same time, newer alternative modalities for diagnosis and treatment response assessment are considered. Molecular imaging entails the use of radioactive probes that exploit molecular targets expressed by microbes or human cells for imaging using hybrid scanners that provide both anatomic and functional features of the disease being imaged. Fluorine-18 fluorodeoxyglucose (FDG) is the most investigated radioactive probe for TB imaging in research and clinical practice. When imaged with positron emission tomography interphase with computed tomography (PET/CT), FDG PET/CT performs better than sputum conversion for predicting treatment outcome. At the end of treatment, FDG PET/CT has demonstrated the unique ability to identify a subset of patients declared cured based on the current standard of care but who still harbor live bacilli capable of causing disease relapse after therapy discontinuation. Our understanding of the pathogenesis and evolution of TB has improved significantly in the last decade, owing to the introduction of FDG PET/CT in TB research. FDG is a non-specific probe as it targets the host inflammatory response to Mycobacterium tuberculosis, which is not specifically different in TB compared with other infectious conditions. Ongoing efforts are geared towards evaluating the utility of newer probes targeting different components of the TB granuloma, the hallmark of TB lesions, including hypoxia, neovascularization, and fibrosis, in TB management. The most exciting category of non-FDG PET probes developed for molecular imaging of TB appears to be radiolabeled anti-tuberculous drugs for use in studying the pharmacokinetic characteristics of the drugs. This allows for the non-invasive study of drug kinetics in different body compartments concurrently, providing an insight into the spatial heterogeneity of drug exposure in different TB lesions. The ability to repeat molecular imaging using radiolabeled anti-tuberculous agents also offers an opportunity to study the temporal changes in drug kinetics within the different lesions during treatment.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lawal IO, Abubakar S, Ankrah AO, et al. Molecular Imaging of Tuberculosis. Semin Nucl Med. 2022. PMID: 35882621. doi:10.1053/j.semnuclmed.2022.07.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。